Revenue
$56.99M
Gross Margin
+97.3%
Operating Margin
-206.2%
Net Margin
-188.2%
Income statement waterfall for Tango Therapeutics (TNGX) — TTM through Q1 2026
Net income: −$107.23M
Margin breakdown for Tango Therapeutics (TNGX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $56.99M | $56.99M |
| Cost of Revenue | −$1.57M | $55.42M |
| Gross Profit | $55.42M | $55.42M |
| Operating Expenses | −$172.95M | −$117.53M |
| Operating Income | −$117.53M | −$117.53M |
| Other Income / Expense | $10.27M | −$107.26M |
| Pre-tax Income | −$107.26M | −$107.26M |
| Tax Benefit | $29.00K | −$107.23M |
| Net Loss | −$107.23M | −$107.23M |
- Revenue$56.99M
- Cost of Revenue−$1.57M
- Gross Profit$55.42M
- Operating Expenses−$172.95M
- Operating Income−$117.53M
- Other Income / Expense$10.27M
- Pre-tax Income−$107.26M
- Tax Benefit$29.00K
- Net Loss−$107.23M
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement